Trial Profile
A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study of the Safety and Efficacy of Topically Applied AN2898 and AN2728 in the Treatment of Patients With Mild-to-Moderate Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2019
Price :
$35
*
At a glance
- Drugs AN 2898 (Primary) ; Crisaborole (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Anacor Pharmaceuticals; Pfizer
- 28 Feb 2014 New trial record
- 27 Feb 2014 Anacor Pharmaceuticals originally reported the results of this study on 12 December 2011, according to a company media release.